tbuckley/cabot-search huggingface dataset:
Immunologic Properties of RA27/3 Rubella Virus Vaccine
Authors: Stanley A. Plotkin
Journal: JAMA (1973)

The Wistar RA27/3 strain of rubella virus was attenuated in WI-38 cell culture, and although it induces predominantly subclinical infection, it is immunogenic both intranasally and subcutaneously. The humoral antibody response to this strain administered either way is characterized by hemagglutination-inhibition, complement-fixation, neutralizing, and precipitin antibody responses closer to those of natural rubella than is the case with other attenuated strains. Those who receive live attenuated Wistar RA27/3 rubella virus vaccine develop a resistance to reinfection similar to that following natural infection without the susceptibility to reinfection manifested by those receiving either live attenuated Cendehill or HPV-77 rubella virus vaccines. The induction of nasal antibodies is correlated with this resistance to reinfection with rubella virus. Intranasally administered RA27/3 vaccine, but not subcutaneously administered RA27/3 vaccine, can be used to boost the antibody titer of subjects previously given Cendehill or HPV-77 vaccines.
Complete angiographic evaluation of renal cancer
Authors: P. C. Kahn
Journal: JAMA (1968)

In 30 patients with renal carcinoma, the standard angiographic examination was supplemented by one or more of the following techniques: selective renal arteriography after epinephrine hydrochloride injection, selective phlebography of the renal veins, selective catheterization of the small retroperitoneal arteries (inferior phrenic, middle adrenal, lumbar, and gonadal), and selective angiography of suspected sites of metastasis. As a result of these additional studies, it was possible to determine more precisely the size and location of the tumor, to evaluate its spread through the renal capsule and adjacent structures, to determine its growth into renal veins, and to detect or verify metastases. This information aided both the planning of therapy and the assessment of prognosis.
Kiwanis International
Authors: O. E. Peterson
Journal: JAMA (1965)

<h3>To the Editor:—</h3> All of us in Kiwanis were delighted to see the salute to our Golden Anniversary inThe Journal, in which your story referred to the two physicians who have been presidents of Kiwanis International. I would like to add to this record of Kiwanis leadership by doctors, one more, who has recently discharged a high position in Kiwanis International. Dr. Arnold Treitman of New York was one of the cochairmen of the highly successful, Golden Anniversary Convention which was held in New York, July 4-8, 1965. Both Dr. and Mrs. Treitman contributed tremendously to the overall success of this convention.
Do readers and peer reviewers agree on manuscript quality?
Authors: A. C. Justice
Journal: JAMA (1994)

<h3>Objective.</h3> —To study readers' judgments of manuscript quality and the degree to which readers agreed with peer reviewers. <h3>Design.</h3> —Cross-sectional study. <h3>Setting.</h3> —<i>Annals of Internal Medicine</i>. <h3>Subjects.</h3> —One hundred thirteen consecutive manuscripts reporting original research and selected for publication. Each of two manuscript versions (one before and one after revision) was judged by two readers, randomly sampled from those who said (based on the title) that they would read the article; one peer reviewer (peer), chosen in the usual way for<i>Annals</i>; and one expert in clinical research methods (expert). Each judge completed an instrument that included a 10-point subjective summary grade of manuscript quality. <h3>Main Outcome Measures.</h3> —Agreement on the 10-point summary grade of manuscript quality between reader-expert, reader-peer, and reader-reader. <h3>Results.</h3> —Readers and peers gave high grades (77% and 73% gave a grade of 5 or better, respectively), while experts were more critical (52% gave a grade of 5 or better;<i>P</i>&lt;.0001). Agreement was relatively high among judge groups (in all cases, &gt;69%) but agreement beyond chance was poor (κ&lt;0.04). One third of readers (33%) thought that the manuscript had little relevance to their work. <h3>Conclusion.</h3> —Readers, like most peer reviewers, are generally satisfied with the quality of manuscripts but would like research articles to be more relevant to their clinical practice. (<i>JAMA</i>. 1994;272:117-119)
PWE-079 Longitudinal Assessment of Epithelial and Immune Cell Changes Following Ileostomy Closure in Patients with Ulcerative Colitis
Authors: J Landy, H O Al-Hassi, E R Mann, S T Peake, P J Ciclitira, J Nicholls, S K Clark, S C Knight, A L Hart
Journal: Gut (2013)

<h3>Introduction</h3> The interactions between microbiota, epithelial barrier and innate immune responses are important in the pathogenesis of IBD. The ileo-anal pouch offers a unique opportunity to study these inter-relationships before the onset of disease. There are few data regarding tight junction expression or dendritic cell (DC) characteristics following restorative proctocolectomy (RPC). We aimed to assess the relationship between changes in epithelial tight junction expression, dendritic cell phenotype and mucosal cytokine production over the first year following RPC for ulcerative colitis (UC). <h3>Methods</h3> Mucosal biopsy samples were taken from the same UC patients undergoing RPC, from the ileostomy afferent loop, the pouch pre-ileostomy closure (P0) and the pouch 6 and 12 months post-ileostomy closure (n = 5). Eptihelial cells expression of zona occludens (ZO)-1, claudin 1 and claudin 2 and DC expression of TLR 2 and 4, CCR9, β7 and CD40 were measured by multicolour flow cytometry. Cytokines were assessed by multiplex ELISA of biopsy supernatants. The paired t-test was used for statistical analysis. <h3>Results</h3> Epithelial expression of claudin 2 was increased (p = 0.04) at 6 months and remained elevated at 12 months. No changes were seen in ZO-1 or claudin 1 expression. There was a significant increase in β7 expression on lamina propria DC (p = 0.02), but no differences in DC TLR or CD40 expresssion were seen at 6 months. DC expression of β7 was further elevated (p = 0.005) as well as significantly increased TLR 4 and CD40 expression (p = 0.04). No cytokines were found to be elevated at 6 months, but at 12 months there was a trend towards increased IL6 (p = 0.05). <h3>Conclusion</h3> In patients with UC, altered tight junction expression with increased epithelial expression of the “pore-forming” tight junction claudin 2 was an early event after ileostomy closure that preceded the onset of mucosal inflammation. In parallel, more lamina propria DC expressed gut homing markers possibly in response to increased exposure to the changing microbial signals and a more permeable epithelial barrier. These changes in parallel may lead to increased microbial stimulation of DC with increased TLR and co-stimulatory molecule expression that could predispose to the development of inflammation. <h3>Disclosure of Interest</h3> J. Landy Grant/Research Support from: The Broad Foundation, H. Al-Hassi: None Declared, E. Mann: None Declared, S. Peake: None Declared, P. Ciclitira: None Declared, J. Nicholls: None Declared, S. Clark: None Declared, S. Knight: None Declared, A. Hart: None Declared
Correction: Conflicts of Interest at Medical Journals: The Influence of Industry-Supported Randomised Trials on Journal Impact Factors and Revenue – Cohort Study
Authors: Andreas Lundh, Marija Barbateskovic, AsbjÃ¸rn HrÃ³bjartsson, Peter C. GÃ¸tzsche
Journal: PLoS Medicine (2011)

Background: Transparency in reporting of conflict of interest is an increasingly important aspect of publication in medical journals.Publication of large industry-supported trials may generate many citations and journal income through reprint sales and thereby be a source of conflicts of interest for journals.We investigated industry-supported trials' influence on journal impact factors and revenue.Methods and Findings: We sampled six major medical journals (Annals of Internal Medicine, Archives of Internal Medicine, BMJ, JAMA, The Lancet, and New England Journal of Medicine [NEJM]).For each journal, we identified randomised trials published in 1996-1997 and 2005-2006 using PubMed, and categorized the type of financial support.Using Web of Science, we investigated citations of industry-supported trials and the influence on journal impact factors over a ten-year period.We contacted journal editors and retrieved tax information on income from industry sources.The proportion of trials with sole industry support varied between journals, from 7% in BMJ to 32% in NEJM in 2005-2006.Industry-supported trials were more frequently cited than trials with other types of support, and omitting them from the impact factor calculation decreased journal impact factors.The decrease varied considerably between journals, with 1% for BMJ to 15% for NEJM in 2007.For the two journals disclosing data, income from the sales of reprints contributed to 3% and 41% of the total income for BMJ and The Lancet in 2005-2006.Conclusions: Publication of industry-supported trials was associated with an increase in journal impact factors.Sales of reprints may provide a substantial income.We suggest that journals disclose financial information in the same way that they require them from their authors, so that readers can assess the potential effect of different types of papers on journals' revenue and impact.
Report of the Committee for the Assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents
Journal: JAMA (1975)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
KT5823 Differentially Modulates Sodium Iodide Symporter Expression, Activity, and Glycosylation between Thyroid and Breast Cancer Cells
Authors: Sasha Beyer, Aparna Lakshmanan, Yu-Yu Liu, Xiaoli Zhang, Irene Wapnir, Albert Smolenski, Sissy Jhiang
Journal: Endocrine Reviews (2011)

Na+/I− symporter (NIS)-mediated iodide uptake into thyroid follicular cells serves as the basis of radioiodine therapy for thyroid cancer. NIS protein is also expressed in the majority of breast tumors, raising potential for radionuclide therapy of breast cancer. KT5823, a staurosporine-related protein kinase inhibitor, has been shown to increase thyroid-stimulating hormone-induced NIS expression, and thus iodide uptake, in thyroid cells. In this study, we found that KT5823 does not increase but decreases iodide uptake within 0.5 h of treatment in trans-retinoic acid and hydrocortisone-treated MCF-7 breast cancer cells. Moreover, KT5823 accumulates hypoglycosylated NIS, and this effect is much more evident in breast cancer cells than thyroid cells. The hypoglycosylated NIS is core glycosylated, has not been processed through the Golgi apparatus, but is capable of trafficking to the cell surface. KT5823 impedes complex NIS glycosylation at a regulatory point similar to brefeldin A along the N-linked glycosylation pathway, rather than targeting a specific N-glycosylated site of NIS. KT5823-mediated effects on NIS activity and glycosylation are also observed in other breast cancer cells as well as human embryonic kidney cells expressing exogenous NIS. Taken together, KT5823 will serve as a valuable pharmacological reagent to uncover mechanisms underlying differential NIS regulation between thyroid and breast cancer cells at multiple levels.
Atropine Methonitrate and Isoprenaline in Bronchial Asthma
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CME FORUM
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Keloids
Authors: Jared Jagdeo, Eva Kerby, Donald Alexander Glass
Journal: JAMA Dermatology (2021)

KeloidsKeloids are large, firm, raised scars that occur after skin injury. KeloidKeloids are firm, raised scars that occur after skin injury.Unlike other scars, they grow beyond the borders of injured skin into surrounding normal skin.Keloids frequently occur on the chest, shoulders, back, and ears, most commonly in patients with darker skin tones. C H E S T Surgical scar keloid Types of scarsKeloids may cause itch, pain, and soreness to touch.They may also become irritated and appear infected.Treatment for early keloids can include a combination of steroid injections, radiation, and other methods.Some keloids can be surgically removed, but many grow back.Keloids may be caused by surgical wounds, burns, acne, vaccinations, piercings, and tattoos.Keloids can also occur without a known cause. FOR MORE INFORMATIONKeloid and hypertrophic scars https://dermnetnz.org/topics/keloids-and-hypertrophic-scar/Keloid
A 2 year old child with rash and fever
Authors: R. Sharma
Journal: BMJ (2003)

Acromesomelic dysplasia Maroteaux type (AMDM) is an autosomal recessive disorder belonging to the group of acromesomelic dysplasias. AMDM is characterised by severe dwarfism with shortening of the middle and distal segments of the limbs. An AMDM gene has recently been mapped to human chromosome 9p13-q12 by homozygosity mapping in four consanguineous families. Here, we show linkage of the disease gene to chromosome 9p13-q12 in four of five consanguineous AMDM families and its exclusion in a fifth family with two children affected with a mild form of the disease. This study suggests that genetic heterogeneity accounts for the variable clinical and radiological severity of AMDM.
Competence and Quality of Medical Care
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
News and Notices
Journal: British Journal of Dermatology (2012)

British Journal of DermatologyVolume 167, Issue 6 p. 1399-1399 News and Notices First published: 26 November 2012 https://doi.org/10.1111/bjd.12122Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume167, Issue6December 2012Pages 1399-1399 RelatedInformation
International Comments
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Bullying
Authors: Lorna Powell
Journal: BMJ (2011)

Common in healthcare Bullying affects up to half of people in the United Kingdom at some point during their working lives and is particularly common among healthcare employees.12 Doctors and medical students are no exception, and it is a problem faced by many medical students and newly qualified doctors in the UK and internationally.34 When the British Medical Association asked a group of students if they had ever been the victim of bullying, intimidation, or discrimination while at medical school, more than a third of those questioned felt they had experienced such behaviour during their training.1 The Advisory, Conciliation and Arbitration Service (ACAS) specialises in workplace relationships. It defines bullying as “offensive, intimidating, malicious or insulting behaviour, an abuse or misuse of power through means intended to undermine, humiliate, denigrate or injure the recipient. Bullying or harassment may be by an individual against an individual (perhaps by someone in a position of authority such as a manager or supervisor) or involve groups of people. It may be obvious or it may be insidious.” Bullying can take many forms (see box). #### Bullying
Biopsy and prognosis of malignant melanoma
Authors: E. Epstein
Journal: JAMA (1969)

In a personal series of 559 patients with black lesions on the skin, only 2.1% had malignant melanomas; about 98% were not melanomatous. Of 31 instances in which melanoma was suspected, the diagnosis was proven by histopathologic examination in only 12 (38.7%). Since melanoma surgery is mutilating, biopsy studies would be helpful if they were not damaging to the patient. Of the 193 surgically treated localized malignant melanomas reported to the California Tumor Registry from 1950 to 1954, incomplete excision was performed in 115 cases. Definitive surgery was done later in 90 of these cases— as much as one week later in 73. A comparison of the survival rates of the 115 patients on whom biopsies were done with those of the 55 patients on whom definitive surgery was performed immediately showed no deleterious effect from the delayed surgery.
Nuclear Weapons Testing Fallout and Thyroid Disease
Authors: Ralph E. Lapp
Journal: JAMA (1994)

<h3>To the Editor.</h3> —The article by Kerber et al<sup>1</sup>concludes that from zero to six thyroid carcinomas were probably caused by radioiodine fallout from the Nevada nuclear tests. This is based on a finding of 2.6 excess thyroid carcinomas among 2473 subjects. Eight thyroid carcinoma cases were observed— four in a Utah population and four in an Arizona group. Five of these carcinomas were found among 1419 subjects whose thyroid exposure was calculated to be less than 50 mGy. In this group one would expect a natural incidence of 3.1 thyroid carcinomas, leading to an excess of 1.9. This means that three fourths of the excess carcinoma is expressed in subjects with less than a 50-mGy dose to the thyroid. Actually, the excess carcinomas should be proportional to the collective thyroid dose, ie, to the number of subjects multiplied by their mean dose. Those with less than 50-mGy doses
Electrocardiography
Authors: Laurence B. Ellis
Journal: New England Journal of Medicine (1947)

IN 1940 a progress report was published to help orient physicians in general regarding the value and limitations of electrocardiography in the diagnosis and evaluation of heart disease.1 The present article is not strictly a progress report. Rather, it is designed for those who have some basic knowledge of the subject but who have lacked time and opportunity to keep abreast of the recent developments in the field. No attempt has been made to review completely the voluminous number of articles that have been published in recent years; only a few major points are considered.A recent development has been . . .